Abstract
Ankylosing spondylitis (AS) is a chronic inflammatory disorder involving the sacroiliac joints (SIJs), spine and less frequently the peripheral joints. Traditionally, it is well recognised that AS is a challenging disease to manage due to the lack of effective therapeutic options. Current evidence would suggest this has changed and there are now a number of therapies available that provide persistent control of inflammatory symptoms with improvement in daily function. NSAIDs remain the first step in patient treatment. Sulphasalazine may be effective in peripheral arthritis and there are emerging data to support its use in early inflammatory back pain. Studies have shown that pamidronate and steroid injection into SIJ have a symptom-modifying effect in AS. Current data suggest that anti-TNF treatment promises early benefit which is likely to continue in the longer term. Treatment with biologics should be considered sooner rather than later in the management of AS.
Similar content being viewed by others
References
Feldtkeller E, Khan MA, van der Heijde D, van der Linden S, Braun J (2003) Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int 23(2):61–66
Carette S, Graham D, Little H, Rubenstein J, Rosen P (1983) The natural disease course of ankylosing spondylitis. Arthritis Rheum 26(2):186–190. doi:10.1002/art.1780260210
Gran JT, Skomsvoll JF (1997) The outcome of ankylosing spondylitis; a study of 100 patients. Br J Rheumatol 36(7):766–771. doi:10.1093/rheumatology/36.7.766
Ward MM (1999) Health-related quality of life in ankylosing spondylitis: a survey of 175 patients. Arthritis Care Res 12(4):247–255. doi:10.1002/1529-0131(199908)12:4<247::AID-ART3>3.0.CO;2-H
Dagfinrud H, Vollestad NK, Loge JH, Kvien TK, Mengshoel AM (2005) Fatique in patients with ankylosing spondylitis: a comparison with the general population and associations with clinical and self-reported measures. Arthritis Rheum 53(1):5–11. doi:10.1002/art.20910
Ward MM (2002) Functional disability predicts total costs in patients with ankylosing spondylitis. Arthritis Rheum 46(1):223–231. doi:10.1002/1529-0131(200201)46:1<223::AID-ART498>3.0.CO;2-#
Kobelt G, Andlin-Sobocki P, Brophy S, Jonsson L, Calin A, Braun J (2004) The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (remicade). Rheumatology 43(9):1158–1166. doi:10.1093/rheumatology/keh271
Boonen A, van der Heijde D, Landewe R, Guillemin F, Rutten-van Molken M, Dougados M et al (2003) Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries. Ann Rheum Dis 62(8):732–740. doi:10.1136/ard.62.8.732
van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27(4):361–368. doi:10.1002/art.1780270401
Rudwaleit M, van der Heijde D, Khan MA, Braun J, Sieper J (2004) How to diagnose axial spondyloarthritis early. Ann Rheum Dis 63(5):535–543. doi:10.1136/ard.2003.011247
Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J (2004) Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 63(6):665–670. doi:10.1136/ard.2003.016386
Dougados M, Dijkmans B, Khan M, Maksymowych W, van der Linden S, Brandt J (2002) Conventional treatment for ankylosing spondylitis. Ann Rheum Dis 61(Suppl 3):40–50
Shekelle PG, Woolf SH, Eccles M, Grimshaw J (1999) Clinical guidelines: developing guidelines. BMJ 318(7183):593–596
Brandt J, Haibel H, Cornely D et al (2000) Successful treatment of active ankylosing spondylitis with anti-tumour necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 43(6):1346–1352. doi:10.1002/1529-0131(200006)43:6<1346::AID-ANR18>3.0.CO;2-E
Van Den Bosch F, Kruithof E, Baeten D, De Keyser F, Mielants H, Veys EM (2000) Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 59(6):428–433. doi:10.1136/ard.59.6.428
Kruithof E, Van den Bosch F, Baeten D et al (2002) Repeated infusions of infliximab, a chimeric anti-TNF alpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis 61(3):207–212. doi:10.1136/ard.61.3.207
Stone M, Salonen D, Lax M, Payne U, Lapp V, Inman R (2001) Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis. J Rheumatol 28(7):1605–1614
Maksymowych WP, Jhangri GS, Lambert RG et al (2002) Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol 29(5):959–965
Braun J, Brandt J, Listing J et al (2002) Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359(9313):1187–1193. doi:10.1016/S0140-6736(02)08215-6
Braun J, Brandt J, Listing J et al (2003) Long term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum 48(8):2224–2233. doi:10.1002/art.11104
Braun J, Brandt J, Listing J et al (2005) Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 64(2):229–234. doi:10.1136/ard.2004.025130
Braun J, Baraliakos X, Brandt J et al (2005) Persistent clinical response to the anti TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology 44(5):670–676. doi:10.1093/rheumatology/keh584
Braun J, Baraliakos X, Listing J et al (2008) Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis 67(3):340–345. doi:10.1136/ard.2007.075879
Sieper J, Baraliakos X, Listing J et al (2005) Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 years of treatment with the anti-tumour necrosis factor agent infliximab. Rheumatology 44(12):1525–1530. doi:10.1093/rheumatology/kei046
Braun J, Baraliakos X, Golder W et al (2003) Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum 48(4):1126–1136. doi:10.1002/art.10883
Marzo-Ortega H, McGonagle D, Jarrett S et al (2005) Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. Ann Rheum Dis 64(11):1568–1575. doi:10.1136/ard.2004.022582
Perez-Guijo VC, Cravo AR, Castro Mdel C, Font P, Munoz-Gomariz E, Collantes-Estevez E (2007) Increased efficacy of infliximab associated with methotrexate in ankylosing spondylitis. Joint Bone Spine 74(3):254–258. doi:10.1016/j.jbspin.2006.08.005
Baraliakos X, Listing J, Rudwaleit M, Brandt J, Sieper J, Braun J (2005) Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab. Ann Rheum Dis 64(10):1462–1466. doi:10.1136/ard.2004.033472
Baraliakos X, Listing J, Brandt J et al (2007) Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. Rheumatology 46(9):1450–1453. doi:10.1093/rheumatology/kem166
van der Heijde D, Dijkmans B, Geusens P et al (2005) Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomised, placebo-controlled trial (ASSERT). Arthritis Rheum 52(2):582–591. doi:10.1002/art.20852
Baraliakos X, Listing J, Brandt J et al (2005) Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 7(3):439–444. doi:10.1186/ar1693
Baraliakos X, Listing J, Rudwaleit M et al (2007) Safety and efficacy of readministration of infliximab after long term continuous therapy and withdrawal in patients with ankylosing spondylitis. J Rheumatol 34(3):510–515
Gossec L, Le Henanff A, Breban M et al (2006) Continuation of treatment with infliximab in ankylosing spondylitis: 2-yr open follow up. Rheumatology 45(7):859–862. doi:10.1093/rheumatology/kel015
Keeling S, Oswald A, Russell AS, Maksymowych WP (2006) Prospective observational analysis of the efficacy and safety of low-dose (3 mg/kg) Infliximab in ankylosing spondylitis: 4-year follow up. J Rheumatol 33(3):558–561
Cheung PP, Tymms KE, Wilson BJ et al (2008) Inflximab in severe active ankylosing spondylitis with spinal ankylosis. Intern Med J 38(6):396–401. doi:10.1111/j.1445-5994.2007.01599.x
Marzo-Ortega H, McGonagle D, O’Connor P, Emery P (2001) Efficacy of etanercept in the treatment of the entheseal pathology in resistant Spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum 44(9):2112–2117. doi:10.1002/1529-0131(200109)44:9<2112::AID-ART363>3.0.CO;2-H
Gorman JD, Sack KE, Davis JC (2002) Treatment of ankylosing spondylitis by inhibition of tumour necrosis factor alpha. N Engl J Med 346(18):1349–1356. doi:10.1056/NEJMoa012664
Davis JC, Van der Heijde D, Braun J et al (2003) Recombinant human tumour necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomised controlled trial. Arthritis Rheum 48(11):3230–3236. doi:10.1002/art.11325
Baraliakos X, Davis J, Tsuji W, Braun J (2005) Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept. Arthritis Rheum 52(4):1216–1223. doi:10.1002/art.20977
Davis JC, Van der Heijde DM, Braun J et al (2005) Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis 64(11):1557–1562. doi:10.1136/ard.2004.035105
Davis JC, Van der Heijde DM, Braun J et al (2007) Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 67(3):346–352. doi:10.1136/ard.2007.078139
Brandt J, Khariouzov A, Listing J et al (2003) Six-month results of a double- blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 48(6):1667–1675. doi:10.1002/art.11017
Brandt J, Listing J, Haibel H et al (2005) Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology 44(3):342–348. doi:10.1093/rheumatology/keh475
Baraliakos X, Brandt J, Listing J et al (2005) Outcome of patients with active ankylosing spondylitis after twor years of therapy with etanercept: clinical and magnetic esonance imaging Data. Arthritis Rheum 53(6):856–863. doi:10.1002/art.21588
Rudwaleit M, Baraliakos X, Listing J, Brandt J, Sieper J, Braun J (2005) Magnetic resonance imaging of the spine and the sacroiliac joint in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept. Ann Rheum Dis 64(9):1305–1310. doi:10.1136/ard.2004.032441
Calin A, Dijkmans BA, Emery P et al (2004) Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 63(12):1594–1600. doi:10.1136/ard.2004.020875
Braun J, McHugh N, Singh A, Wajdula JS, Sato R (2007) Improvement in patient- reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly. Rheumatology 46(6):999–1004. doi:10.1093/rheumatology/kem069
Haibel H, Rudwaleit M, Brandt HC et al (2006) Adalimumab reduces spinal symptoms in active ankylosing spondyltis: clinical and magnetic resonance imaging results of a fifty-two week open-label trial. Arthritis Rheum 54(2):678–681. doi:10.1002/art.21563
van der Heijde D, Kivitz A, Schiff MH et al (2006) Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54(7):2136–2146. doi:10.1002/art.21913
van der Heijde D, Pangan AL, Schiff MH et al (2008) Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis. Ann Rheum Dis 67(9):1218–1221. doi:10.1136/ard.2007.082529
Tan AL, Marzo-Ortega H, O’ Connor P, Fraser A, Emery P, McGonagle D (2004) Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Ann Rheum Dis 63(9):1041–1045. doi:10.1136/ard.2004.020800
Haibel H, Rudwaleit M, Listing J, Sieper J (2005) Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis 64(2):296–298. doi:10.1136/ard.2004.023176
Blue Cross Blue Shield Association Technology Evaluation Centre (BCBS) (2003) Off label uses for tumor necrosis factor inhibitors in ankylosing spondylitis, ulcerative colitis, and psoriasis, Chicago, p 61
Canadian Coordinating Office for Health Technology Assessment (CCOHTA) (2004) Infliximab (Remicade TM) for the treatment of ankylosing spondylitis, Ottawa, p 54
Canadian Coordinating Office for Health Technology Assessment (CCOHTA) (2004) Etanercept for the treatment of ankylosing spondylitis, Ottawa, p 53
BSR guidelines for prescribing TNF alpha blockers in adults with ankylosing spondylitis (2004) The British Society for Rheumatology. http://www.rheumatology.org.uk
Barkham N, Kong KO, Tennant A et al (2005) The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis. Rheumatology 44(10):1277–1281. doi:10.1093/rheumatology/keh713
Sampaio-Barros PD, Costallat LT, Bertolo MB, Neto JF, Samara AM (2000) Methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol 29(3):1160–1162
Biasi D, Carletto A, Caramaschi P, Pacor ML, Maleknia T, Bambara LM (2000) Efficacy of methotrexate in the treatment of ankylosing spondylitis: a three year open study. Clin Rheumatol 19(2):114–117. doi:10.1007/s100670050027
Altan L, Bingol U, Karakoc Y, Aydiner S, Yurtkuran M (2001) Clinical investigation of methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol 30(5):255–259. doi:10.1080/030097401753180318
Roychowdhury B, Bintley-Bagot S, Bulgen DY, Thompson RN, Tunn EJ, Moots RJ (2002) Is methotrexate effective in ankylosing spondylitis? Rheumatology 41(11):1330–1332. doi:10.1093/rheumatology/41.11.1330
Gonzalez-lopez L, Garcia-Gonzalez A, Vazquez-Del-Mercado M, Munoz-Valle JF, Gamez-Nava JI (2004) Efficacy of methotrexate in ankylosing spondylitis: a randomized, double blind, placebo controlled trial. J Rheumatol 31(8):1568–1574
Haibel H, Brandt HC, Song IH et al (2007) No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. Ann Rheum Dis 66(3):419–421. doi:10.1136/ard.2006.054098
Chen J, Liu C, Lin J (2006) Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 4:CD004524 Review
Feltelius N, Hallgren R (1986) Sulphasalazine in ankylosing spondylitis. Ann Rheum Dis 45(5):396–399. doi:10.1136/ard.45.5.396
Nissila M, Lehtinen K, Leirisalo-Repo M, Luukkainen R, Mutru O, Yli-kerttula U (1988) Sulphasalazine in the treatment of ankylosing spondylitis. A twenty-six week, placebo-controlled trial. Arthritis Rheum 31(9):1111–1116. doi:10.1002/art.1780310905
Davis MJ, Dawes PT, Beswick E, Lewin IV, Stanworth DR (1989) Sulphasalazine therapy in ankylosing spondylitis: its effect on disease activity, immunoglobulin A and the complex immunoglobulin A-alpha-1-antitrypsin. Br J Rheumatol 28(5):410–413. doi:10.1093/rheumatology/28.5.410
Taylor HG, Beswick EJ, Dawes PT (1991) Sulphasalazine in ankylosing spondylitis. A radiological, clinical and laboratory assessment. Clin Rheumatol 10(1):43–48. doi:10.1007/BF02208032
Kirwan J, Edwards A, Huitfeldt B, Thompson P, Currey H (1993) The course of established ankylosing spondylitis and the effects of sulphasalazine over 3 years. Br J Rheumatol 32(8):729–733. doi:10.1093/rheumatology/32.8.729
Dougados M, vam der Linden S, Leirisalo-Repo M et al (1995) Sulfasalazine in the treatment of spondyloarthropathy. A randomized, multi center, double-blind, placebo-controlled study. Arthritis Rheum 38(5):618–627. doi:10.1002/art.1780380507
Clegg DO, Reda DJ, Weisman MH et al (1996) Comparison of sulphasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 39(12):2004–2012. doi:10.1002/art.1780391209
Clegg DO, Reda DJ, Abdellatif M (1999) Comparison of sulfazalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondyloarthropathies. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 42(11):2325–2329. doi:10.1002/1529-0131(199911)42:11<2325::AID-ANR10>3.0.CO;2-C
Braun J, Zochling J, Baraliakos X et al (2006) Efficacy of sulphasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis- a multicentre randomised controlled trial. Ann Rheum Dis 65(9):1147–1153. doi:10.1136/ard.2006.052878
Ferraz MB, Tugwell P, Goldsmith CH, Atra E (1990) Meta analysis of sulfasalazine in ankylosing spondylitis. J Rheumatol 17(11):1482–1486
Chen J, Liu C (2006) Is sulfazalazine effective in ankylosing spondylitis? A systematic review of randomized controlled trials. J Rheumatol 33(4):722–731
Haibel H, Rudwaleit M, Braun J, Sieper J (2005) Six months open label trial of leflunamide in active ankylosing spondylitis. Ann Rheum Dis 64(1):124–126. doi:10.1136/ard.2003.019174
van Denderen JC, van der Paardt M, Nurmohamed MT, de Ryck YM, Dijkmans BA, van der Horst-Bruinsma IE et al (2005) Double blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis. Ann Rheum Dis 64(12):1761–1764. doi:10.1136/ard.2005.036491
Dougados M, Gueguen A, Nakache JP et al (1999) Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial. Rheumatology 38(3):235–244. doi:10.1093/rheumatology/38.3.235
Dougados M, Behier JM, Jolchine I et al (2001) Efficacy of celebrex, a cyclooxygenase 2- specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional non steroidal anti inflammatory drug. Arthritis Rheum 44(1):180–185. doi:10.1002/1529-0131(200101)44:1<180::AID-ANR24>3.0.CO;2-K
Wanders A, Heijde D, Landewe R et al (2005) Nonsteroidal anti-inflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomised controlled trial. Arthritis Rheum 52(6):1756–1765. doi:10.1002/art.21054
van der Heijde D, Baraf HS, Ramos-Remus C et al (2005) Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: result of a fifty-two week, randomized, controlled study. Arthritis Rheum 52(4):1205–1215. doi:10.1002/art.20985
Gossec L, van der Heijde D, Melian A et al (2005) Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis. Ann Rheum Dis 64(11):1563–1567. doi:10.1136/ard.2004.029611
Sieper J, Klopsch T, Richter M et al (2008) Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study. Ann Rheum Dis 67(3):323–329. doi:10.1136/ard.2007.075309
Maksymowych WP, Jhangri GS, Leclercq S, Skeith K, Yan A, Russell AS (1998) An open study of pamidronate in the treatment of refractory ankylosing spondylitis. J Rheumatol 25(4):714–717
Maksymowych WP, Lambert R, Jhangri GS et al (2001) Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous pamidronate therapy. J Rheumatol 28(1):144–155
Maksymowych WP, Jhangri GS, Fitzgerald AA et al (2002) A six month randomised, controlled, double- blind, dose-response comparison of Intravenous pamidronate (60 mg vs 10 mg) in the treatment of non steroidal anti-inflammatory drug refractory ankylosing spondylitis. Arthritis Rheum 46(3):766–773. doi:10.1002/art.10139
Haibel H, Brandt J, Rudwaleit M, Soerensen H, Sieper J, Braun J (2003) Treatment of active ankylosing spondylitis with pamidronate. Rheumatology 42(8):1018–1020. doi:10.1093/rheumatology/keg256
Grover R, Shankar S, Aneja R, Marwaha V, Gupta R, Kumar A (2006) Treatment of ankylosing spondylitis with pamidronate: an open label study. Ann Rheum Dis 65(5):688–689. doi:10.1136/ard.2005.041392
Maugars Y, Mathis C, Vilon P, Prost A (1992) Corticosteriod injection of the sacroiliac joint in patients with seronegative spondyloarthropathy. Arthritis Rheum 35(5):564–568. doi:10.1002/art.1780350512
Braun J, Bollow M, Seyrekbasan F et al (1996) Computed tomography guided corticosteriod injection of the sacroiliac joint in patients with spondylarthropathy with sacroilitis: clinical outcome and follow-up by dynamic magnetic resonance imaging. J Rheumatol 23(4):659–664
Maugars Y, Mathis C, Berthelot JM, Charlier C, Prost A (1996) Assessment of the efficacy of sacroiliac corticosteriod injections in spondyloarthropathies: a double-blind study. Br J Rheumatol 35(8):767–770. doi:10.1093/rheumatology/35.8.767
Gunaydin I, Pereira PL, Daikeler T et al (2000) Magnetic resonance imaging guided corticosteriod injection of the sacroiliac joints in patients with therapy resistant spondyloarthropathy: a pilot study. J Rheumatol 27(2):424–428
Hanly JG, Mitchell M, MacMillan L, Mosher D, Sutton E (2000) Efficacy of sacroiliac corticosteriod injections in patients with inflammatory spondyloartropathy: results of a 6 month controlled study. J Rheumatol 27(3):719–722
Rudwaleit M, Khan MA, Sieper J (2005) The challenge of diagnosis and classification in early ankylosing spondylitis. Do we need new criteria? Arthritis Rheum 52(4):1000–1008. doi:10.1002/art.20990
Kenny JB, Hughes PL, Whitehouse GH (1990) Discovertebral destruction in ankylosing spondylitis: the role of computed tomography and magnetic resonance imaging. Br J Radiol 63(750):448–455
Jevtic V, Kos-Golja M, Rozman B, McCall I (2000) Marginal erosive discovertebral “Romanus” lesions in ankylosing spondylitis demonstrated by contrast enhanced Gd-DTPA magnetic resonance imaging. Skeletal Radiol 29(1):27–33. doi:10.1007/s002560050005
Goh L, Suresh P, Gafoor A, Hughes P, Hickling P (2008) Disease activity in longstanding ankylosing spondylitis: a correlation of clinical and magnetic resonance imaging findings. Clin Rheum 27(4):449–455. doi:10.1007/s10067-007-0726-7
Muche B, Bollow M, Francois RJ, Sieper J, Hamm B, Braun J (2003) Anatomic structures involved in early and late-stage sacroilitis in spondyloarthritis: a detailed analysis by contrast-enhanced magnetic resonance imaging. Arthritis Rheum 48(5):1374–1384. doi:10.1002/art.10934
Bredella MA, Steinbach LS, Morgan S, Ward M, Davis JC (2006) MRI of the sacroiliac joint in patients with moderate to severe ankylosing spondylitis. AJR Am J Roentgenol 187(6):1420–1426. doi:10.2214/AJR.05.1423
Maksymowych WP, Landewe R (2006) Imaging in ankylosing spondylitis. Best Pract Res Clin Rheumatol 20(3):507–519. doi:10.1016/j.berh.2006.03.006
Rudwaleit M, Schwarzlose S, Hilgert ES, Listing J, Braun J, Sieper J (2008) MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis 67(9):1276–1281. doi:10.1136/ard.2007.073098
van der Heijde D, Landewe R, Einstein S et al (2008) Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 58(5):1324–1331. doi:10.1002/art.23471
Acknowledgments
We are grateful to K.J. Goh for his considerable support during preparation of this manuscript. The authors have declared no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Goh, L., Samanta, A. A systematic medline analysis of therapeutic approaches in ankylosing spondylitis. Rheumatol Int 29, 1123–1135 (2009). https://doi.org/10.1007/s00296-009-0973-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-009-0973-9